ABSTRACT
INTRODUCTION
Antibiotic resistance continues to be a global public health crisis [1] . The Centers for Disease
Control and Prevention (CDC) state that resistant bacteria cause over two million infections in the United States annually, with a mortality rate of over 20,000 individuals per year [2, 3] . Curtailing resistance through infection control measures is key to mitigating the threat and decreasing the spread of these organisms [4] . Once patients are infected, however, optimizing antimicrobial therapy becomes paramount. This is a challenge secondary to the declining availability of active agents and dwindling pipeline of novel [19] [20] [21] [22] . This review will focus on several unconventional combinations with colistin that have demonstrated possible clinical utility.
METHODS
Literature associated with the combination of colistin and glycopeptides, lipopeptides, and lipoglycopeptides for the targeted treated of ACB was included in this review. All relevant English-language peer-reviewed publications were accessed through PUBMED using the following medical subject heading (MeSH) terms: vancomycin, daptomycin, telavancin, glycopeptide, lipopeptide, lipoglycopeptide, colistin, Acinetobacter baumannii, and combination therapy. Citations within these references were also assessed for inclusion. Publications in abstract form were included in the review if these abstracts were presented as part of professional meetings.
The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
DISCUSSION

Unconventional Approaches to Treatment
Studies with Glycopeptide Antibiotics
Until recently little was known about combinations of colistin and antimicrobials with exclusive activity against Gram-positive bacteria. Novel combinations of colistin plus glycopeptide and lipopeptide antibiotics have recently been examined, yielding positive results [23, 24] . Vancomycin is a glycopeptide antibiotic that has become a mainstay in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) over the past two decades that works by inhibiting peptidoglycan synthesis in the bacterial cell wall [25, 26] . The proposed mechanism of synergy relates to the cellmembrane permeabilizing ability of colistin.
Colistin causes an electrostatic interaction with LPS (lipid A), disrupting the outer membrane of the Gram-negative bacteria. This allows the otherwise large and hydrophobic vancomycin molecules to pass through the outer LPS layer and reach the site of action at the cell wall [23, 24] .
Synergy between vancomycin and colistin in MDRAB was first described by Gordon et al. [23] with in vitro checkerboard assays, synergy Etests, and time-kill curves, against 39 [33] . This lack of clinical correlation may be secondary to the small sample size of 57 patients. There was, however, still a significant increase in the risk of developing renal failure across any acute kidney injury network (AKIN) stage (p = 0.04). The combination was then studied in a larger cohort of critically ill patients infected with Gram-negative bacteria, including, but not limited to, patients with MDRAB [34] . Of the 184 patients included, 99 patients were infected with MDRAB, 48 received the combination of glycopeptide and colistin. The remaining Gram-positive co-infection (41.2% versus 0.0%, p\0.001). Thirty-day mortality was not significantly different between those treated with the combination and those treated with monotherapy (33.8% versus 29.6%). Although infection with MDRAB was an independent predictor of mortality, through cox regression the receipt of the combination for C5 days was shown to be protective for 30-day survival.
There was no difference in renal toxicity between the patients who received glycopeptides and those that did not.
Studies with Lipopeptide Antibiotics
In addition to the glycopeptides, the lipopeptide antibiotic daptomycin and lipoglycopeptide antibiotic telavancin have been investigated in combination with colistin (Table 1) . Telavancin has a dual mechanism of action wherein it acts as glycopeptide antibiotics by inhibiting transpeptidation and transglycosylation, the peptidoglycan polymerization step of cell wall synthesis, as well as altering cell membrane permeability via changing membrane potential [35, 36] . Similar to vancomycin and teicoplanin, the combination with colistin has demonstrated significant synergy in vitro and improved survival in an in vivo invertebrate model [30, 37] . Daptomycin has a unique and not yet fully elucidated mechanism of action that causes calcium-dependent destabilization of the cell membrane as well as altering the cell wall through septal defects [38] . As is the case with glycopeptides, the presence of a LPS outer membrane in Gram-negative bacteria protects against daptomycin binding to the cellular membrane.
In a 2012 abstract, Malmberg et al. [39] initially demonstrated possible synergistic activity of daptomycin in combination with colistin against 15 clinical isolates of MDRAB.
The combination of 2.3 mg/L colistin and 2.1 mg/L daptomycin was effective in 13 isolates, however, regrowth after 4 h was seen.
Galani et al. [31] studied the combination of daptomycin and colistin against 14 MDRAB clinical isolates. Of these, four were resistant to colistin. Synergy was tested using Etests, MICs, and time-kill curves. Daptomycin Etests were placed on agar supplemented with subinhibitory concentrations (0.5 9 MIC) of colistin. The timekill curves were completed with cation-adjusted Muller-Hinton broth over a 24-h period using 0.259, 0.59, and 1 9 MIC of colistin for susceptible strains, 5 mg/L colistin for resistant strains, and 10 mg/L of daptomycin. In the Etests, subinhibitory concentrations of colistin were able to decrease the daptomycin MIC to 4-128 mg/L in the colistin-susceptible isolates but colistin concentrations upwards of 5 mg/L had no effect on daptomycin MICs for resistant isolates. A total of 30 isolate-concentration isolates that were exposed to 0.5 9 MIC colistin bactericidal activity occurred in five (50%), compared to zero isolates exposed without daptomycin. Nine of 10 isolates exposed to colistin at 1 9 MIC demonstrated bactericidal activity with no regrowth at 24 h. It appears the possible benefits of the daptomycin-colistin combination were limited to colistin- [40] . Daptomycin has to interact with the negatively charged phospholipids within the cell membrane.
Randall et al. [40] hypothesized that the substantially lower amount of phospholipids (one-third that of S. aureus) in Gram-negatives such as E. coli may result in the lack of activity of daptomycin. After an in vitro study of the destabilizing effects of daptomycin against liposomes comprised both E. coli and S. aureus, the authors concluded that major differences in phospholipid composite affect daptomycin activity in Gram-negatives. 
